Compromised antigen presentation ranks among the top mechanisms that render cancers non-immunogenic (non-responsive to immune ...

Twenty-five received irradiation, and only 2 were ultimately considered cured. There were 71 basal-cell lesions, with 64 three-year cures. In 12 mixed or basosquamous lesions, there were 11 three ...

As I've been looking into the cost of the best cell phone plans for a decade now, I'm extremely familiar with what different carriers charge for different plans and how much data you get in ...

Here’s how it works. Knowing whether you have the best cell phone plan for your needs can put an end to those nagging doubts about whether you're spending too much for wireless service each month.

CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable ...

However, how spindle tethering complexes read the cell polarity axis and how spindle attachment is coupled to mitotic progression remains poorly understood. We explore these questions in Drosophila ...

Mast cell activation syndrome, or disease (MCAS), is a condition that causes mast cells to release these substances too frequently, resulting in severe allergic reactions. After detecting an ...

At the heart of GaN’s potential lies its crystal polarity. While both nitrogen-polar (N-polar) and gallium-polar (Ga-polar) GaN exist, N-polar variants demonstrate superior performance.

“I’ll ask if someone has ever had skin cancer, and they will tell me, ‘No, just a basal cell.’” Basal and squamous cell carcinomas are the most common types of skin cancer; more than 3 ...

Nkarta is laying off a third of its workforce, and more than half its executive team, in a bid to survive long enough to see if an experimental cell therapy it’s developing will show promise against ...

The leading eye-care company Alcon on Wednesday said it has acquired a majority stake in Aurion Biotech, capping months of legal wrangling over the future of the cell therapy developer. As part of the ...